A

Amgen

Makes biotech medicines for serious illnesses

Regulatory Labeling Manager

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree or master's degree and 9 to 12 years of directly related experience in Regulatory Affairs, labeling compliance, artwork management, quality, or a related pharmaceutical or biotechnology function; equivalent combinations of education and relevant experience may be considered.
  • Experience supporting EU and/or global labeling processes, including Product Information updates, linguistic review, mock-up review, artwork review, approval workflows, and implementation activities.
  • Familiarity with EU labeling requirements, approved Product Information, country-specific implementation needs, and coordination with regional affiliates or local regulatory contacts.
  • Experience working with labeling management systems, artwork management systems, or document management platforms such as Veeva Vault or similar tools.
  • Understanding of end-to-end labeling implementation, from approved regulatory text through translation, linguistic review, artwork creation, review, approval, release, and market implementation.
  • Experience coordinating Summary of Product Characteristics, Package Leaflet, outer labeling, inner labeling, mock-ups, and printed packaging components.
  • Ability to manage multiple labeling deliverables in a matrix organization while meeting deadlines and maintaining compliance.
  • Experience working across international teams, external vendors, and multiple time zones.
  • Experience coordinating with translation vendors, artwork vendors, Regulatory Affairs, Quality, Operations, Supply Chain, and regional or local stakeholders.
  • Ability to identify risks, gaps, inconsistencies, or discrepancies in labeling documentation.
  • Ability to support process improvement initiatives and contribute to efficient, compliant, and scalable labeling workflows.
  • Familiarity with inspection readiness expectations, standard operating procedure compliance, documentation standards, quality-controlled processes, and audit-ready record maintenance.
Responsibilities
  • Coordinate day-to-day labeling activities to support timely and compliant implementation of approved labeling changes across EU and global markets.
  • Manage labeling change requests, track deliverables, monitor timelines, and maintain accurate records in applicable labeling, artwork, or document management systems.
  • Serve as an operational point of contact for labeling activities, providing guidance to internal stakeholders on labeling processes, document requirements, formats, and timelines.
  • Ensure labeling updates align with approved Product Information, internal procedures, quality standards, and market-specific implementation requirements.
  • Identify potential compliance risks, delays, inconsistencies, or documentation gaps and escalate issues to appropriate stakeholders for timely resolution.
  • Support EU labeling activities across applicable centralized, decentralized, mutual recognition, and national procedures, as relevant.
  • Coordinate updates to EU Product Information components, including the Summary of Product Characteristics, Package Leaflet, outer labeling, inner labeling, mock-ups, and related packaging text.
  • Support alignment of labeling content with approved Marketing Authorisations, regulatory commitments, internal procedures, and country-specific requirements.
  • Coordinate with regional and local Regulatory Affairs contacts to gather requirements, clarify expectations, resolve queries, and support implementation of approved labeling changes.
  • Track EU labeling milestones, review comments, approvals, and implementation status to ensure visibility across stakeholders and delivery against agreed timelines.
  • Facilitate linguistic review activities for EU labeling updates with affiliates, local regulatory contacts, translation vendors, and internal reviewers.
  • Coordinate review of country-specific translations to support consistency, accuracy, and alignment with approved source Product Information.
  • Track linguistic review comments, queries, responses, and approvals to ensure timely completion of country-specific labeling requirements.
  • Support resolution of translation queries, terminology discrepancies, formatting issues, and Member State or local affiliate comments with relevant stakeholders.
  • Maintain accurate documentation of linguistic review activities, decisions, approvals, and final approved local texts in applicable systems.
  • Coordinate artwork review and approval workflows to ensure packaging components accurately reflect approved labeling text, technical requirements, and market-specific information.
  • Support review of artwork components, including cartons, labels, leaflets, blisters, foils, and other printed packaging materials, as applicable.
  • Collaborate with artwork vendors, Regulatory Affairs, Quality, Supply Chain, Operations, and local affiliates to support timely artwork creation, review, approval, release, and implementation.
  • Review artwork-related documentation for completeness, consistency, version control, and alignment with approved Product Information and internal procedures.
  • Monitor artwork timelines and follow up with stakeholders to address delays, open comments, approval bottlenecks, or implementation risks.
  • Maintain accurate records of artwork decisions, review comments, approvals, version history, and implementation evidence in relevant systems.
  • Partner with global, regional, and local stakeholders across Regulatory Affairs, Quality, Operations, Supply Chain, and affiliates to support compliant and timely labeling implementation.
  • Coordinate with external vendors, including translation providers and artwork vendors, to ensure deliverables meet agreed quality expectations, timelines, and service-level requirements.
  • Assist in monitoring vendor performance, identifying service gaps, and escalating issues that may impact labeling compliance, linguistic review, artwork approval, or implementation timelines.
  • Participate in project meetings with internal and external partners to align priorities, clarify requirements, resolve operational challenges, and complete milestones.
  • Support collaboration across time zones through clear communication, structured follow-up, and accurate tracking of open actions.
  • Contribute to continuous improvement initiatives focused on labeling processes, EU labeling workflows, linguistic review coordination, artwork review, templates, trackers, and system usage.
  • Support inspection readiness by ensuring labeling documentation, approval records, standard operating procedure adherence, and implementation evidence are complete, accurate, and readily available.
  • Collect and analyze labeling operations data to identify trends, process gaps, cycle-time delays, and opportunities to improve efficiency, compliance, and transparency.
  • Assist in developing or refining training materials, job aids, process maps, and work instructions to promote consistent execution of labeling procedures.
  • Provide guidance and operational support to peers and junior team members on labeling compliance processes, EU labeling requirements, artwork review, linguistic review, and quality expectations.
  • Stay informed of emerging EU labeling expectations, regulatory requirements, and industry practices that may affect Product Information, artwork processes, or labeling implementation activities.
Desired Qualifications
  • Experience supporting EU and/or global labeling processes, including Product Information updates, linguistic review, mock-up review, artwork review, approval workflows, and implementation activities.
  • Familiarity with EU labeling requirements, approved Product Information, country-specific implementation needs, and coordination with regional affiliates or local regulatory contacts.
  • Experience working with labeling management systems, artwork management systems, or document management platforms such as Veeva Vault or similar tools.
  • Understanding of end-to-end labeling implementation, from approved regulatory text through translation, linguistic review, artwork creation, review, approval, release, and market implementation.
  • Experience coordinating Summary of Product Characteristics, Package Leaflet, outer labeling, inner labeling, mock-ups, and printed packaging components.
  • Demonstrated ability to manage multiple labeling deliverables in a matrix organization while meeting deadlines and maintaining compliance.
  • Experience working across international teams, external vendors, and multiple time zones.
  • Experience coordinating with translation vendors, artwork vendors, Regulatory Affairs, Quality, Operations, Supply Chain, and regional or local stakeholders.
  • Strong analytical and problem-solving skills, with attention to detail and ability to identify risks, gaps, inconsistencies, or discrepancies in labeling documentation.
  • Ability to support process improvement initiatives and contribute to efficient, compliant, and scalable labeling workflows.
  • Familiarity with inspection readiness expectations, standard operating procedure compliance, documentation standards, quality-controlled processes, and audit-ready record maintenance.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.